Trial backs role for Lynparza in second-line prostate cancer

In the 340-patient trial,   Lynparza was compared to hormonal treatment with Pfizer’s Xtandi (enzalutamide) or Johnson &Johnson’s Zytiga (abiraterone acetate) in this second-line setting, focusing on patients ... AZ is also conducting a phase 3

Bayer bags FDA nod for early prostate cancer drug darolutamide

Now its approved, Nubeqa will go head-to-head in the non-metastatic CRPC market with J&J’s Erleada (apalutamide) – a follow-up to its Zytiga (abiraterone) brand which is ... Zytiga is only approved for metastatic CRPC and, as Xtandi and Erleada were

Bayer gains FDA priority review for prostate cancer drug

Once approved, the drug will go up against Johnson &Johnson’s Zytiga (with the first generics now reaching the market), its follow-up Erleada, and Pfizer/Astellas' Xtandi. ... The big question is whether that will be enough to differentiate the drug

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga. Bayer and Orion have put some meat on the bones of their phase 3 trial of darolutamide in non-metastatic ... Darolutamide is facing some entrenched, heavyweight rivals in the market for

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]